tbuckley/cabot-search huggingface dataset:
Real-Time Monitoring of Somatostatin Receptor-cAMP Signaling in Live Pituitary
Authors: Stefan Jacobs, Davide Calebiro, Viacheslav O. Nikolaev, Martin J. Lohse, Stefan Schulz
Journal: Endocrine Reviews (2010)

Fluorescence resonance energy transfer using genetically encoded biosensors has proven to be a powerful technique to monitor the spatiotemporal dynamics of cAMP signals stimulated by Gs-coupled receptors in living cells. In contrast, real-time imaging of Gi-mediated cAMP signals under native conditions remains challenging. Here, we describe the use of transgenic mice ubiquitously expressing the highly sensitive cAMP sensor exchange protein directly activated by cAMP 1-camps for cAMP imaging in living pituitary slices and primary pituitary cells. This technique can be widely used to assess the contribution of various pituitary receptors, including individual Gi protein-coupled somatostatin receptors, to the regulation of cAMP levels under physiologically relevant settings.
Left-Sided Patent Ductus Arteriosus and Right-Sided Aortic Arch: Angiocardiographic Findings in Three Cases
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Massive spontaneous renal cyst hemorrhage
Authors: C. D. Brown
Journal: JAMA (1978)

MASSIVE spontaneous renal hemorrhage (bleeding without trauma) is rare. Usually, communication with the renal collecting system exists and gross hematuria is the presenting complaint. On occasion, there is no communication with the collecting system, and blood accumulates as a hematoma in the renal parenchyma (intrarenal hematoma) beneath the renal capsule (subcapsular hematoma), or beyond Gerota's fascia (pararenal hematoma).<sup>1</sup>Demonstration of bleeding during angiography in a nontraumatized kidney has been observed in only a few instances.<sup>2</sup>Demonstration of a bleeding site in the wall of a benign renal cyst and presentation as a pararenal hematoma with massive spontaneous hematuria has not, to our knowledge, been previously reported. <h3>Report of a Case</h3> A 65-year-old man was first seen in the emergency room with uncontrolled, massive renal bleeding. No history of recent or remote kidney trauma could be obtained. Two years before, the patient had had a brief, spontaneous, nonpainful episode
OP0178 Tocilizumab-effects on growth impairment in systemic juvenile idiopathic arthritis
Authors: T. Miyamae, T. Nozawa, M. Kikuchi, T. Kizawa, T. Imagawa, S. Yokota
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> The safety and efficasy of anti-IL-6 receptor monoclonal antibody, tocilizumab (TCZ) has been reported in children with systemic juvenile idiopathic arthritis (s-JIA). <h3>Objectives</h3> Growth analysis during the study was performed. <h3>Methods</h3> Forty-five s-JIA patients (8.1±4.2 years) who completed phase-III study of TCZ were enrolled. Mean standard deviation score (SDS) for height, changes in SDS from baseline (ΔSDS), correlation between ΔSDS and several factors such as age, disease duration, corticosteroid dose exposure were evaluated. Yearly height velocity analysis was made with 28 patients who had data for 1 year prior to TCZ administration and received TCZ for more than 1 year. <h3>Results</h3> Thirty-eight of 45 (84%) obtained clinical response at week 144. The baseline SDS-height was -2.7±2.0 with inverse correlation with disease duration. Significant improvement was seen in height velocity SDS changes from 1 year prior to 1 year posterior to baseline (n=28, -6.0±4.0 to-2.5±3.9, <i>p</i>=0.0064). Reduction in corticosteroid exposure was significantly associated with improvement in height velocity SDS (<i>p</i>=0.0027). Standardized height velocity continued to improve over 3 years of TCZ, whereas average daily prednisolone equivalent dose showed inverse correlation (n=17, Figure). <h3>Conclusions</h3> Growth impairments evidenced by SDS-height were more prominent in patients with longer standing disease. Catch up growth was observed in patients who required less or no corticosteroid during TCZ treatment. <h3>References</h3> Yokota S, et al. Lancet. 2008 Mar 22;371(9617):998-1006. <h3>Disclosure of Interest</h3> None Declared
Miscellaneous Topics
Authors: T Rösch
Journal: Endoscopy (2001)

Thin transnasal endoscopes (diameter 5 - 6 mm) have been on the market for some time, and have been shown to be better tolerated than endoscopy via the oral route (without sedation) - possibly at the loss of image quality, although this is difficult to quantify. In a multicenter study in France involving 500 patients, the transnasal endoscope was compared with the standard gastroscope introduced transorally, and only a local spray was allowed. The rate of failure to intubate was higher with the transnasal route (6.8 % vs. 1.7 %), and visibility was better with the standard endoscope (significant only for the cardia). The transnasal route was better tolerated by patients (willingness to repeat endoscopy 90 % versus 75 %), although 25 % of patients reported pain in the nostrils [1]. A similar endoscope was used in routine practice in 1327 consecutive outpatients, with a mean examination time of 3.1 min (we had thought that Olympic records in gastroscopy were over) and a completion rate of 95 %, with good patient tolerance [2]. Two groups presented the next step - use of a battery-powered ultrathin endoscope (3 mm in diameter), which is intended only for esophageal examination; its accuracy in detecting disease was substantially inferior to that of standard EGD (sensitivities for various disorders 54 - 84 %) [3]. Another study found that patient acceptance of unsedated esophagoscopy, even with this very thin endoscope, was limited - only 50 % of the 48 patients who underwent both ultrathin and conventional endoscopy stated that they would prefer the thin scope in the future [4]. It remains to be seen whether slim endoscopes will be able to establish themselves, by improving both patient acceptance and image quality.
EPIBRONCHIAL PRESSURE POUCHES OF THE ESOPHAGUS.
Journal: JAMA (1900)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The future of critical care: lessons from the COVID-19 crisis
Authors: None The Lancet Respiratory Medicine
Journal: The Lancet Respiratory Medicine (2020)

The COVID-19 pandemic has put a huge strain on critical care resources worldwide, as systems have struggled to provide high-quality care for a surge of critically ill patients. The response of clinicians and researchers—in providing care in extraordinary circumstances and in rapidly establishing research programmes to explore the potential of a range of preventive and therapeutic approaches—has been impressive. Lessons can be learned from the challenges encountered and the successes achieved as we consider future directions for critical care.
Book Review The Medical Department of the United States Army in the World War . Volume IV. Activities Concerning Mobilization Camps and Ports of Embarkation. By Maj. Albert S. Bowen, M. C. Prepared under the direction of Maj. Gen. M. W. Ireland, the Surgeon General. Washington: U. S. Government Printing Office, 1928. Ppg. 494.
Journal: New England Journal of Medicine (1929)
Virology, New York
Journal: JAMA (1969)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Clinical Diabetes Mellitus and Hyperinsulinism
Journal: JAMA (1941)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Sense and Sensibility
Authors: William B. Bean
Journal: JAMA (1960)

Any clinician interested in improving his ability to use his senses of sight, hearing, touch, taste, and smell, in sharpening his sensibility, and in seeing how one can use just the right word in just the right way, will be delighted to study Richard Asher's contribution to the sense and sensibility of medicine which embellishes the Lettsomian Lectures for 1959. Asher is a physician who has already established a wide reputation as a medical stylist and who knows well the influence of words in making or preventing medical progress. He is a downto-earth clinician. He is the namer, though not the inventor, of the Munchausen Syndrome. As a writer of medical essays of great distinction, Richard Asher already has a following wherever elegant medical English is treasured. He is one of a diminishing— indeed, nearly extinct—tribe of physicians who are keen observers, sound thinkers, and articulate writers. The exquisite simplicity
OP0093 Il-38 overexpression induces anti-inflammatory effects in mice arthritis models and in human macrophages in vitro
Authors: M-A Boutet, A Najm, G Bart, R Brion, S Touchais, V Trichet, P Layrolle, C Gabay, G Palmer-Lourenco, F Blanchard, B Le Goff
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> IL-38 is a newly characterized cytokine that belongs to the IL-1 family. This cytokine is expressed in the rheumatoid arthritis (RA) synovial tissue (1) and IL-38 deficient mice have exacerbated arthritis (2). <h3>Objectives</h3> This work aims to analyze the effect of IL-38 overexpression in the joints of arthritic mice, in human macrophages and synovial fibroblasts <i>in vitro</i>. <h3>Methods</h3> Articular injections of an adeno-associated virus (AAV2/8) encoding IL-38 were performed in Collagen-Induced Arthritis (CIA), K/BxN Serum Transfer-Induced Arthritis (STIA) and Antigen-Induced Arthritis (AIA) in mice. The effect of IL-38 overexpression was evaluated through clinical scores, immunohistochemistry, microCT, Luminex and RT-qPCR analysis. THP-1 monocytes/macrophages were transduced with a lentiviral vector to overexpress IL-38. Effect of conditioned media from these transduced THP-1 cells was also tested on primary culture: M1 macrophages and fibroblast-like synoviocytes from RA patients (RA-FLS). <h3>Results</h3> Clinical inflammatory scores were significantly decreased after AAV IL-38 injection in joints of mice with CIA and STIA, but not AIA. This decrease was accompanied by reduced macrophage infiltration and a decreased expression of Th17 expressed cytokines (IL-17, IL-23, IL-22, TNFα). However, IL-38 overexpression had no effect on cartilage or bone destruction. <i>In vitro</i>, the THP-1 monocytic cell line expressed less IL-6, TNFα and IL-23 after IL-38 overexpression. Conditioned media from these cells, containing released IL-38, was also able to exert an anti-inflammatory effect on human primary M1 macrophages and RA-FLS by reducing their IL-23 (M1) and IL-6 (M1 and RA-FLS) expression. <h3>Conclusions</h3> This study shows for the first time that IL-38 overexpression attenuates the severity of experimental arthritis in two mice arthritis models. IL-38 may exert its anti-inflammatory effects by decreasing the production of pro-inflammatory cytokines by macrophages and synovial fibroblasts. This effect can lead to the development of novel treatment strategies in arthritis. <h3>References</h3> Boutet MA, Bart G, Gahier M, Amiaud J, Brulin B, Charrier C, Morel F, Lecron JC, RolliDerkinderen M, Boureille A, et al. Distinct expression of IL-36α, β, γ and their antagonists IL-36Ra and IL-38 in Psoriasis, Rheumatoid Arthritis and Crohn9s disease. Clin Exp Immunol, 2015. doi: 10.1111/cei.12761. Takenaka, S., Kaieda, S., Kawayama, T., Matsuoka, M., Kaku, Y., Kinoshita, T., Sakazaki, Y., Okamoto, M., Tominaga, M., Kanesaki, K., et al. (2015). IL-38: A new factor in rheumatoid arthritis. Biochem. Biophys. Rep. 4, 386–391. <h3>Disclosure of Interest</h3> None declared
Phase I dose-escalation trial of high-dose melphalan (M) with palifermin (P) for cytoprotection followed by autologous stem cell transplantation (ASCT) for myeloma (MM) patients with normal renal function (NRF).
Authors: M. H. Abidi, N. Tageja, Z. S. Al-Kadhimi, J. Abrams, S. Cronin, M. Ventimiglia, L. J. Ayash, L. G. Lum, V. Ratanatharathorn, J. P. Uberti
Journal: Journal of Clinical Oncology (2010)

6543 Background: Melphalan (M) exhibits a steep, log-linear dose effect with a potential for dose escalation to overcome M resistance. Severe oral mucositis (OM) at M ≥ 200 mg/m2 precludes dose escalation due to significant morbidity. P as a cytoprotective agent has demonstrated efficacy in reducing intensity and duration of OM in pts receiving intensive chemo-radiotherapy. We designed this study to determine the MTD of M in pts with NRF when used with P. Methods: We enrolled 19 pts from 07/2007 to 09/2009. We report data on 18 evaluable pts as 1 pt was removed. Pts were 18-74 years old,stage 2/3, ECOG PS ≤ 2, no active OM & eligible for ASCT. Dose-escalation proceeded (three-pt cohorts), at 20 mg/m2 increments, depending on the dose limiting toxicities (DLT). Level (L) 1 began at M 200 mg/m2 with P 60 mcg/kg/d, given as I.V. bolus on Day -5,-4, -3 and Day +1, +2 and +3 (PBSCs infused on Day 0). M was given on D-2 up to and including 280 mg/m2 (n = 6). If no symptomatic grade ≥ 3 DLTs were noted by day +30, an additional cohort of 3 pts were entered at the next dose level. Dose escalations were to stop if ≥ 2 DLTs occurred at M dose; with that dose declared as the MTD. Grade 3/ 4 diarrhea and ≥ grade 3 cardiac toxicity was considered DLT; grade 3/4 hematological toxicity was acceptable. The grade of OM was assessed daily according to the WHO oral-toxicity scale (grade 0-4). Results: The overall incidence of OM ≥ grade 3 was 44% (8/18) with a median duration of OM 10 days (range 4 -20 d). Only 1 pt in L 1 group developed grade 4 OM. Two out of 6 pts given M 280 mg/m2 did not develop any OM. All 18 pts were evaluable for response at D+100 and there were no deaths. Atrial fibrillation occurred in 1/6 pts treated with M 280 mg/m2. The most common adverse events included rash (18 events, no grade 3), elevation of amylase (10, 4 grade 3-asymptomatic) and lipase (5, 2 grade 3 -asymptomatic) and edema (11, no grade 3). 11 pts (61%) required IV opioid analgesics; none needed TPN/NG feeding. Tumor responses were noted at all M doses. Conclusions: P has permitted safe dose escalation of M up to 280 mg/m2 with acceptable toxicity, thus reaching the cumulative dosage of M administered in tandem ASCT. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Biovitrum Pharma
Reply
Authors: Thomas Berg, Florian van Bömmel
Journal: Hepatology (2005)

We thank Dr. Del Poggio and colleagues for their comments outlining their experience in treating hepatitis B e antigen (HBeAg)-negative patients with tenofovir. In their study they showed that even a tenofovir dosage of 75 mg/day was able to induce and maintain virological response in patients with and without genotypic lamivudine-resistant hepatitis B virus (HBV) infection. From this they postulated that a tenofovir escalation study with a dose ranging from 75 to 300 mg/day should be performed, also pointing out that the economic burden of this therapy also justifies such a study. Analyzing the data presented we only can warn against drawing such far-reaching conclusions. First, there are striking differences regarding the disease activity of the two populations of HBV-infected patients seen in Treviglio and Berlin.1 In our study all lamivudine-resistant patients had high HBV DNA levels (mean, 2.7 × 109 copies/mL), whereas only 1 of the 10 chronically HBV-infected patients from Italy had detectable viremia in the presence of a lamivudine-resistant mutation when he was switched from lamivudine to tenofovir. Second, there is general agreement that early and effective reduction of HBV replication is most important in preventing the selection of drug-resistant mutants.2, 3 Therefore, our observed rapid antiviral effect of tenofovir even in the presence of high viral load is a strong argument in favor of using the safe dose of 300 mg, which in addition may guarantee the prevention of mutants better than dosages of 75 mg. In this respect, our recent observation that we could reduce the viral load even below 6 IU/mL as verified by the more sensitive real-time PCR technology (Cobas TaqMan, Roche Diagnostics Systems, Pleasanton, CA; detection limit 6 IU/mL) in 50% of the tenofovir-treated patients already at week 48 strongly speaks for the use of this kind of tenofovir dosing and the probability to cope effectively even with minimal residual HBV replication (van Bömmel F and Berg T, unpublished data, 2005). Thomas Berg M.D.*, Florian van Bömmel M.D.*, * Medizinische Klinik mit Schwerpunkt Hepatologie und Gastroenterologie, Charité - Campus Virchow-Klinikum, Universitätsmedizin Berlin, Berlin, Germany
QUANTITATIVE HEREDITY.
Journal: JAMA (1898)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Pseudomembranous colitis. A fatal case following prophylactic cephaloridine therapy
Authors: J. Tan
Journal: JAMA (1979)

DIARRHEA and pseudomembranous colitis are recognized complications of antibiotic use. Clindamycin hydrochloride<sup>1</sup>has been implicated in most of the cases, but chloramphenicol sodium succinate,<sup>2</sup>ampicillin sodium,<sup>3</sup>lincomycin hydrochloride monohydrate,<sup>4,5</sup>and tetracycline hydrochloride<sup>6,7</sup>may also cause the disease. Combinations of antibiotics that have included a cephalosporin drug have been implicated in several reports of this disorder.<sup>8</sup>However, we are aware of only two case reports of colitis following the use of cephalosporin alone.<sup>9,10</sup>This report describes a fatal case of cephaloridine-associated colitis. <h3>Report of a Case</h3> A 67-year-old woman underwent vaginal hysterectomy for uterine prolapse on Oct 5, 1978. On the same day, preoperatively, she received 1.0 g of cephaloridine intramuscularly prophylactically and then 0.5 g intravenously every six hours postoperatively. There was no history of gastrointestinal disorders, and she had been receiving no medications prior to hospital admission. On the first postoperative day,